Buscopan Use in Pregnancy
The evidence provided does not address Buscopan (hyoscine butylbromide) safety in pregnancy - the FDA drug labels 1 refer to buspirone (an anxiolytic), not Buscopan, which are completely different medications. Based on general medical knowledge and the absence of specific contraindications in the research evidence examining its use during labor, hyoscine butylbromide can be used cautiously during pregnancy, particularly in the second and third trimesters.
Safety Profile During Pregnancy
Hyoscine butylbromide is an anticholinergic antispasmodic that has been studied extensively during labor without significant safety concerns. Multiple randomized controlled trials have examined its use in pregnant women during active labor 2, 3, 4, 5, 6 with consistent findings:
- No adverse neonatal outcomes were reported across studies, with comparable APGAR scores between treatment and placebo groups
- No significant maternal complications were documented
- The drug has been used safely during the active phase of labor in term pregnancies
Clinical Use During Labor
The research evidence demonstrates that hyoscine butylbromide has been administered during labor with the following patterns:
Dosing in labor studies:
- 20 mg intravenously as a single dose during active labor 2, 4
- 40 mg intravenously or intramuscularly 5, 6
- Administered once cervical dilation reaches 3-4 cm (active phase)
Efficacy findings:
- Reduces first stage of labor duration by 23-32% 4, 6
- One recent high-quality trial 2 found no significant effect on labor duration in nulliparous women at risk of prolonged labor, suggesting efficacy may vary by population
- Reduces opioid analgesic requirements by up to 60% 6
Important Caveats
Trimester considerations:
- Most safety data comes from term pregnancies (third trimester) during labor
- First trimester use has limited safety data
- The drug's quaternary ammonium structure limits placental transfer, which theoretically reduces fetal exposure
Clinical context matters:
- The medication is primarily indicated for smooth muscle spasm (gastrointestinal, biliary, urogenital)
- During pregnancy, it has been most extensively studied for labor augmentation
- For non-labor indications during pregnancy, risk-benefit assessment is essential
Contraindications to consider:
- Avoid in patients with glaucoma, myasthenia gravis, or megacolon
- Use caution with tachycardia or urinary retention
The absence of teratogenic signals in the available labor studies and the drug's limited systemic absorption support its reasonable use when clinically indicated, particularly in the second and third trimesters. However, as with any medication during pregnancy, use the lowest effective dose for the shortest duration necessary.